Viatris Stock Performance
| VTRS Stock | USD 9.25 0.15 1.65% |
The entity has a beta of 0.15, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Viatris' returns are expected to increase less than the market. However, during the bear market, the loss of holding Viatris is expected to be smaller as well. At this point, Viatris has a negative expected return of -0.43%. Please make sure to validate Viatris' maximum drawdown, as well as the relationship between the daily balance of power and relative strength index , to decide if Viatris performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Viatris has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 1.65 | Five Day Return (0.64) | Year To Date Return (25.52) | Ten Year Return (85.25) | All Time Return 18.4 K |
Forward Dividend Yield 0.0528 | Payout Ratio | Last Split Factor 3:2 | Forward Dividend Rate 0.48 | Dividend Date 2025-03-18 |
1 | Disposition of 12876 shares by Theodora Mistras of Viatris at 12.45 subject to Rule 16b-3 | 01/03/2025 |
2 | Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/07/2025 |
3 | Acquisition by Anthony Mauro of 29858 shares of Viatris subject to Rule 16b-3 | 02/10/2025 |
4 | Earnings Preview Viatris Q4 Earnings Expected to Decline | 02/20/2025 |
5 | Viatris Misses Estimates, Cash Flow Up | 02/27/2025 |
6 | Disposition of 1546 shares by Scott Smith of Viatris at 9.37 subject to Rule 16b-3 | 02/28/2025 |
7 | Disposition of 81761 shares by Rajiv Malik of Viatris subject to Rule 16b-3 | 03/03/2025 |
8 | Disposition of 35816 shares by Rajiv Malik of Viatris at 9.37 subject to Rule 16b-3 | 03/04/2025 |
9 | Viatris to Present at the Barclays 27th Annual Global Healthcare Conference | 03/05/2025 |
10 | Acquisition by Scott Smith of 373555 shares of Viatris subject to Rule 16b-3 | 03/06/2025 |
11 | Acquisition by Le Goff Corinne of 1173 shares of Viatris subject to Rule 16b-3 | 03/07/2025 |
12 | Securities Fraud Investigation Into Viatris Inc. Announced Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz | 03/11/2025 |
13 | Securities Fraud Investigation Into Viatris Inc. Announced Investors Who Lost Money Urged To Contact Glancy Prongay Murray LLP, a Leading Securities Fraud Law F... | 03/12/2025 |
14 | Q4 Earnings Highs And Lows Amphastar Pharmaceuticals Vs The Rest Of The Generic Pharmaceuticals Stocks | 03/13/2025 |
15 | Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation VTRS | 03/14/2025 |
| Begin Period Cash Flow | 993.6 M |
Viatris |
Viatris Relative Risk vs. Return Landscape
If you would invest 1,211 in Viatris on December 18, 2024 and sell it today you would lose (286.00) from holding Viatris or give up 23.62% of portfolio value over 90 days. Viatris is currently does not generate positive expected returns and assumes 2.3915% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Viatris, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Viatris Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viatris' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Viatris, and traders can use it to determine the average amount a Viatris' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1778
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VTRS |
Estimated Market Risk
| 2.39 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.43 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Viatris is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viatris by adding Viatris to a well-diversified portfolio.
Viatris Fundamentals Growth
Viatris Stock prices reflect investors' perceptions of the future prospects and financial health of Viatris, and Viatris fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viatris Stock performance.
| Return On Equity | -0.0324 | ||||
| Return On Asset | 0.0249 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 24.06 B | ||||
| Shares Outstanding | 1.19 B | ||||
| Price To Earning | 15.16 X | ||||
| Price To Book | 0.58 X | ||||
| Price To Sales | 0.74 X | ||||
| Revenue | 14.74 B | ||||
| Gross Profit | 6.14 B | ||||
| EBITDA | 10.1 M | ||||
| Net Income | (634.2 M) | ||||
| Cash And Equivalents | 741.9 M | ||||
| Cash Per Share | 0.61 X | ||||
| Total Debt | 15.99 B | ||||
| Debt To Equity | 1.07 % | ||||
| Current Ratio | 1.46 X | ||||
| Book Value Per Share | 15.61 X | ||||
| Cash Flow From Operations | 2.3 B | ||||
| Earnings Per Share | (0.53) X | ||||
| Market Capitalization | 10.86 B | ||||
| Total Asset | 41.5 B | ||||
| Retained Earnings | 3.42 B | ||||
| Working Capital | 3.74 B | ||||
About Viatris Performance
Assessing Viatris' fundamental ratios provides investors with valuable insights into Viatris' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Viatris is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 154.32 | 169.21 | |
| Return On Tangible Assets | (0.04) | (0.04) | |
| Return On Assets | (0.02) | (0.01) | |
| Return On Equity | (0.03) | (0.03) |
Things to note about Viatris performance evaluation
Checking the ongoing alerts about Viatris for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Viatris help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viatris generated a negative expected return over the last 90 days | |
| Viatris has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 14.74 B. Net Loss for the year was (634.2 M) with profit before overhead, payroll, taxes, and interest of 6.14 B. | |
| Over 86.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from businesswire.com: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation VTRS |
- Analyzing Viatris' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viatris' stock is overvalued or undervalued compared to its peers.
- Examining Viatris' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viatris' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viatris' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viatris' stock. These opinions can provide insight into Viatris' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Viatris Stock Analysis
When running Viatris' price analysis, check to measure Viatris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viatris is operating at the current time. Most of Viatris' value examination focuses on studying past and present price action to predict the probability of Viatris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viatris' price. Additionally, you may evaluate how the addition of Viatris to your portfolios can decrease your overall portfolio volatility.